BCL2 inhibitor + MCL1 inhibitor (tested in AMKL and non-AMKL AML models) (Aid et al., 2023); BCL-xL inhibitor + JAK inhibitor (tested in AMKL and non-AMKL AML models) (Kuusanmaki et al., 2023). The gene discussed is BCL2; the disease is acute myeloid leukemia.